{
  "nct_id": "NCT06650579",
  "official_title": "Randomized Controlled Trial of Leuprolide Plus Abiraterone Acetate (AA) Versus Relugolix Plus AA for Advanced Prostate Cancer: The REVELUTION-2 Trial",
  "brief_title": "REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial",
  "cancer_type_display": "A study comparing two hormone therapy combinations for patients with advanced, non-metastatic, or biochemically recurrent prostate cancer undergoing radiation therapy.",
  "cancer_tags": [
    "Recurrent Prostate Carcinoma",
    "Stage III Prostate Cancer AJCC v8",
    "Stage IVA Prostate Cancer AJCC v8"
  ],
  "link_to_trial": "https://clinicaltrials.gov/study/NCT06650579",
  "phase": "Phase 3",
  "recruitment_status": "RECRUITING",
  "last_update_date": "2025-02-21",
  "enrollment": 72,
  "min_age": 18,
  "max_age": null,
  "sex": "MALE",
  "is_metastatic_allowed": false,
  "performance_status_scale": null,
  "performance_status_values": null,
  "min_prior_lines": 0,
  "max_prior_lines": 0,
  "prior_treatments_required": null,
  "prior_treatments_excluded": [
    "Androgen deprivation therapy",
    "Chemotherapy",
    "Immunotherapy",
    "Radiation therapy"
  ],
  "principal_investigator": "Sagar A Patel, MD",
  "site_name": "Emory Proton Therapy Center",
  "contact_email": "bill.zheng@emory.edu",
  "contact_phone": "404-686-6856",
  "locations": [
    {
      "facility": "Emory Proton Therapy Center",
      "status": "RECRUITING",
      "city": "Atlanta",
      "state": "Georgia",
      "zip": "30308",
      "country": "United States",
      "contacts": [
        {
          "name": "Bill Zheng",
          "role": "CONTACT",
          "phone": "404-686-6856",
          "email": "bill.zheng@emory.edu"
        }
      ],
      "geoPoint": {
        "lat": 33.749,
        "lon": -84.38798
      }
    },
    {
      "facility": "Winship at Emory Midtown",
      "status": "RECRUITING",
      "city": "Atlanta",
      "state": "Georgia",
      "zip": "30308",
      "country": "United States",
      "contacts": [
        {
          "name": "Bill Zheng",
          "role": "CONTACT",
          "phone": "404-686-6856",
          "email": "bill.zheng@emory.edu"
        }
      ],
      "geoPoint": {
        "lat": 33.749,
        "lon": -84.38798
      }
    },
    {
      "facility": "Emory University Hospital/Winship Cancer Institute",
      "status": "RECRUITING",
      "city": "Atlanta",
      "state": "Georgia",
      "zip": "30322",
      "country": "United States",
      "contacts": [
        {
          "name": "Sagar A. Patel, MD",
          "role": "CONTACT",
          "phone": "404-686-4835",
          "email": "Sagar.patel@emory.edu"
        },
        {
          "name": "Sagar A. Patel",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "geoPoint": {
        "lat": 33.749,
        "lon": -84.38798
      }
    },
    {
      "facility": "Emory Saint Joseph's Hospital",
      "status": "RECRUITING",
      "city": "Atlanta",
      "state": "Georgia",
      "zip": "30342",
      "country": "United States",
      "contacts": [
        {
          "name": "Bill Zheng",
          "role": "CONTACT",
          "phone": "404-686-6856",
          "email": "bill.zheng@emory.edu"
        }
      ],
      "geoPoint": {
        "lat": 33.749,
        "lon": -84.38798
      }
    }
  ],
  "key_inclusion_summary": [
    "Men â‰¥ 18 years old.",
    "Non-metastatic prostate cancer or non-metastatic, biochemically recurrent prostate cancer.",
    "Plan to undergo curative-intent pelvic radiation therapy.",
    "Plan to undergo up to 24 months of combination androgen deprivation therapy (ADT) plus abiraterone acetate (AA) and prednisone."
  ],
  "key_exclusion_summary": [
    "Metastatic prostate cancer requiring indefinite ADT or chemotherapy.",
    "Prior exposure to androgen deprivation therapy, chemotherapy, immunotherapy, or radiation therapy.",
    "History of cardiac bypass surgery or percutaneous coronary intervention.",
    "History of cardiac pacemaker or defibrillator."
  ]
}